Infliximab as first-line therapy for severe Crohn's disease?
Cohen
Russell D
RD
Department of Medicine, Section of Gastroenterology, University of Chicago Medical Center, Illinois 60637, USA. rcohen@medicine.bsd.uchicago.edu
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D003424:Crohn Disease / Q000188:drug therapy*; D005765:Gastrointestinal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D000069285:Infliximab; D012720:Severity of Illness Index
D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D000069285:Infliximab